

## Temporary Halt on Grant of EMI Options to UK Employees

April 4, 2018

With a generous individual limit of £250,000, companies with a UK presence, group gross assets below £30m (balance sheet test) and fewer than 250 employees often grant potentially tax advantageous Enterprise Management Incentive (EMI) options to their UK employees. EMI options with a market value exercise price can mean no income tax for the employee at exercise and capital gains tax at a special 10% rate on a sale of the shares acquired, provided that occurs more than one year after the date of grant.

The tax advantages of EMI options are dependent on EU State Aid approval and, despite the efforts of the UK government, this approval will expire on Friday, 6 April 2018. The UK government has applied to the European Commission for fresh approval and is currently waiting for the commission's final response. Unfortunately, this response will not be received before 6 April 2018.

The UK tax authorities (HMRC) have <u>confirmed today</u> that EMI options granted up to and including 6 April 2018 will not be affected by the lapse of approval. However, EMI options granted in the period from 7 April 2018 until the EU State Aid approval is received may be treated as non-tax advantaged options (with UK income taxes payable on the profit at exercise).

On this basis, we strongly recommend companies delay granting options intended to qualify as EMI to their UK employees until fresh EU State Aid approval has been given.

Please do not hesitate to contact Paula Holland or Nihara McCormack with any questions.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (AI) in accordance with our AI Principles, may be considered Attorney Advertising and is subject to our legal notices.

## **Key Contacts**

Paula Holland London pholland@cooley.com +44 (0) 20 7556 4250

This information is a general description of the law; it is not intended to provide specific legal advice nor is it intended to create an attorney-client relationship with Cooley LLP. Before taking any action on this information you should seek professional counsel.

Copyright © 2023 Cooley LLP, 3175 Hanover Street, Palo Alto, CA 94304; Cooley (UK) LLP, 22 Bishopsgate, London, UK EC2N 4BQ. Permission is granted to make and redistribute, without charge, copies of this entire document provided that such copies are complete and unaltered and identify Cooley LLP as the author. All other

